Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Mohsen
AddedMar 31, 2024
UpdatedJul 2, 2026
Mohsen

Mohsen

Board Member, ReNetX Bio

Mohsen's Career

ReNetX Bio
ReNetX Bio

New Haven, CT, US

Board Member· Board
SmartPay Solutions
SmartPay Solutions

New Haven, CT, US

Board Member· Board
Thetis Pharmaceuticals
Thetis Pharmaceuticals

Ridgefield, CT, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Mohsen's Career

ReNetX Bio
ReNetX Bio
Seed$9.8M72009New Haven, CT, US
Board Member· Board

Leadership at ReNetX Bio

Sylvia McBrinnSylvia McBrinnBoard Member
Steve StrittmatterSteve StrittmatterCo-Founder
David I ScheerDavid I ScheerBoard Member
Erika SmithErika SmithCo-Founder
George MaynardGeorge MaynardCo-Founder
Erika R SmithErika R SmithCEO

Similar to ReNetX Bio

NeuroCytonixNeuroCytonixRockville, MD, USMedical Treatmentsest. 2017NeuroCytonixRockville, MD, US · est. 2017

NeuroCytonix Inc: A pioneering biotech firm specializing in innovative nervous system regeneration technologies.

Series A · $4M25
Novoron BioscienceNovoron BioscienceSan Diego, CA, USPharmaceutical Therapiesest. 2014Novoron BioscienceSan Diego, CA, US · est. 2014

Biotech firm specializing in pharmaceutical therapies for central nervous system regeneration.

Seed · $13.8M5
RegennovaRegennovaDurham, NC, USMedical Solutionsest. 2022RegennovaDurham, NC, US · est. 2022

Regennova: A biotech firm innovating medical solutions for neurological disorders and inflammatory illnesses.

Angel · $5k5
SmartPay Solutions
SmartPay Solutions
Investment Firm$5.3M282010New Haven, CT, US
Board Member· Board

Leadership at SmartPay Solutions

Gary CardellaGary CardellaFounder
Bob ConerlyBob ConerlyCEO
Stephen HolcombStephen HolcombBoard Member
Thetis Pharmaceuticals
Thetis Pharmaceuticals
Series A$22.9M302011Ridgefield, CT, US
Board Member· Board

Leadership at Thetis Pharmaceuticals

Walter OgierWalter OgierBoard Member
Wayne KlohsWayne KlohsBoard Member
Gary MathiasGary MathiasBoard Member
Frank SciavolinoFrank SciavolinoBoard Member

People Similar to Mohsen

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · KakaoMohamad MakhzoumiMohamad MakhzoumiBoard Member · PagerCheryl MillerCheryl MillerBoard Member · Tyson New VenturesJeffrey WeissJeffrey WeissBoard Member · Clean Energy Venture GroupScott BurtScott BurtBoard Member · Foundation Fighting BlindnessKirill ZaydenmanKirill ZaydenmanBoard Member · Enable DentalReza RajiReza RajiBoard Member · StartX